Cv Sciences (OTC: CVSI)
Cv Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cv Sciences Company Info
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the following segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment focuses on developing cannabinoids to treat medical indications. The company was founded by H. J. Cole, Michael J. Mona, Jr. and Michael J. Mona III on December 9, 2010 and is headquartered in San Diego, CA.
News & Analysis
The 9 Best Marijuana Stocks in October
While most pot stocks fell by a double-digit percentage last month, these nine catapulted higher by at least 16%.
Quietly, CV Sciences Is Succeeding in a Competitive CBD Market
However, one monstrous hurdle remains.
3 Marijuana Stocks That Should Uplist to the Nasdaq or NYSE Next
A move from the over-the-counter exchange to a major U.S. exchange may be coming for this trio of pot stocks.
5 of the Cheapest Pot Stocks Under $5
Each and every one of these marijuana stocks has a lower forward P/E ratio than the S&P 500, but is growing substantially faster.
The 3 Least-Volatile Pot Stocks on the Market
But do low volatility metrics translate to high confidence for these stocks' future prospects?
Is the U.S. Getting on Board With Cannabis Legalization?
Here's what to expect from a government agency that's listening to what people have to say about marijuana legalization.
Better CBD Stock: Charlotte's Web vs. CV Sciences
Which purveyor of high-margin, nonintoxicating cannabis products will earn the largest share of this growing market?
3 Marijuana Stocks You Should Buy, According to This 124-Year-Old Wall Street Firm
These cannabis stocks all offer at least 36% upside.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.